Hong Kong-listed Clover Biopharmaceuticals, Ltd. reported a marginal increase in its issued share capital for April 2026, driven solely by the exercise of employee share options.
Key developments • Issued shares rose by 195,377 to 1,298.23 million, expanding the share base by approximately 0.02%. • All new shares resulted from option exercises: – Pre-IPO Share Option Plan: 7,000 shares issued, reducing outstanding options to 1.50 million. – Post-IPO Share Option Plan: 188,377 shares issued, leaving 42.66 million options outstanding and 72.24 million shares available for future grants. • No treasury shares were held or cancelled during the month. • HKD 0.17 million in cash proceeds were received from the option exercises. • Authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001, equivalent to USD 0.20 million. • The company confirmed that its public float stayed above the 25% minimum threshold required by the Hong Kong Stock Exchange.
The filing, submitted on 6 May 2026, affirms that all securities issuances complied with Hong Kong listing rules and corporate governance requirements.
Comments